AU2002236507A1 - Dap-kinase and hoxa9, two human genes associated with genesis, progression, and aggressiveness of non-small cell lung cancer - Google Patents

Dap-kinase and hoxa9, two human genes associated with genesis, progression, and aggressiveness of non-small cell lung cancer

Info

Publication number
AU2002236507A1
AU2002236507A1 AU2002236507A AU3650702A AU2002236507A1 AU 2002236507 A1 AU2002236507 A1 AU 2002236507A1 AU 2002236507 A AU2002236507 A AU 2002236507A AU 3650702 A AU3650702 A AU 3650702A AU 2002236507 A1 AU2002236507 A1 AU 2002236507A1
Authority
AU
Australia
Prior art keywords
hoxa9
genesis
dap
aggressiveness
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002236507A
Inventor
Li Mao
Chul-So Moon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cangen International
Original Assignee
CANGEN INTERNAT
Cangen International
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CANGEN INTERNAT, Cangen International filed Critical CANGEN INTERNAT
Publication of AU2002236507A1 publication Critical patent/AU2002236507A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002236507A 2000-11-29 2001-11-27 Dap-kinase and hoxa9, two human genes associated with genesis, progression, and aggressiveness of non-small cell lung cancer Abandoned AU2002236507A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25008300P 2000-11-29 2000-11-29
US60/250,083 2000-11-29
PCT/US2001/044620 WO2002044331A2 (en) 2000-11-29 2001-11-27 Dap-kinase and hoxa9, two human genes associated with genesis, progression, and aggressiveness of non-small cell lung cancer

Publications (1)

Publication Number Publication Date
AU2002236507A1 true AU2002236507A1 (en) 2002-06-11

Family

ID=22946248

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002236507A Abandoned AU2002236507A1 (en) 2000-11-29 2001-11-27 Dap-kinase and hoxa9, two human genes associated with genesis, progression, and aggressiveness of non-small cell lung cancer

Country Status (3)

Country Link
US (3) US20030224509A1 (en)
AU (1) AU2002236507A1 (en)
WO (1) WO2002044331A2 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1573024A4 (en) 2001-04-10 2007-08-29 Agensys Inc Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
EP1633892A4 (en) * 2003-06-10 2007-10-24 Univ Boston Detection methods for disorders of the lung
JP5192632B2 (en) * 2003-12-12 2013-05-08 愛知県 A method for identifying the intensity of gene expression in lung cancer tissue
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
EP2360279A1 (en) 2005-04-14 2011-08-24 Trustees Of Boston University Diagnostic for lung disorders using class prediction
JP2008539797A (en) * 2005-05-20 2008-11-20 マイケル ケイ スキナー Methods of diagnosing epigenetic and intergenerational transmission effects of mammalian toxic substances on mammalian germline and methods of treating related diseases
EP2363205A3 (en) 2006-01-11 2014-06-04 Raindance Technologies, Inc. Microfluidic Devices And Methods Of Use In The Formation And Control Of Nanoreactors
WO2007103541A2 (en) 2006-03-09 2007-09-13 The Trustees Of Boston University Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
EP2530167A1 (en) 2006-05-11 2012-12-05 Raindance Technologies, Inc. Microfluidic Devices
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
EP3536396B1 (en) 2006-08-07 2022-03-30 The President and Fellows of Harvard College Fluorocarbon emulsion stabilizing surfactants
WO2008070301A2 (en) * 2006-10-20 2008-06-12 Washington University In St. Louis Predicting lung cancer survival using gene expression
US20100278772A1 (en) 2006-11-20 2010-11-04 The Johns Hopkins University Dna methylation markers and methods of use
WO2008097559A2 (en) 2007-02-06 2008-08-14 Brandeis University Manipulation of fluids and reactions in microfluidic systems
US8592221B2 (en) 2007-04-19 2013-11-26 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
CA2689714A1 (en) * 2007-06-01 2008-12-04 Agendia B.V. Prognostic gene expression signature for non small cell lung cancer patients
CA2700200A1 (en) 2007-09-19 2009-03-26 The Trustees Of Boston University Identification of novel pathways for drug development for lung disease
WO2009045370A2 (en) 2007-09-28 2009-04-09 Intrexon Corporation Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof
EP2297360A1 (en) * 2008-07-02 2011-03-23 Assistance Publique - Hôpitaux de Paris A method for predicting clinical outcome of patients with non-small cell lung carcinoma
EP4047367A1 (en) 2008-07-18 2022-08-24 Bio-Rad Laboratories, Inc. Method for detecting target analytes with droplet libraries
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
EP3415235A1 (en) 2009-03-23 2018-12-19 Raindance Technologies Inc. Manipulation of microfluidic droplets
EP2486409A1 (en) 2009-10-09 2012-08-15 Universite De Strasbourg Labelled silica-based nanomaterial with enhanced properties and uses thereof
EP2517025B1 (en) 2009-12-23 2019-11-27 Bio-Rad Laboratories, Inc. Methods for reducing the exchange of molecules between droplets
US8535889B2 (en) 2010-02-12 2013-09-17 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
WO2012045012A2 (en) 2010-09-30 2012-04-05 Raindance Technologies, Inc. Sandwich assays in droplets
WO2012109600A2 (en) 2011-02-11 2012-08-16 Raindance Technologies, Inc. Methods for forming mixed droplets
EP2675819B1 (en) 2011-02-18 2020-04-08 Bio-Rad Laboratories, Inc. Compositions and methods for molecular labeling
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
EP3216872B1 (en) 2011-06-02 2020-04-01 Bio-Rad Laboratories, Inc. Enzyme quantification
WO2012175562A2 (en) * 2011-06-21 2012-12-27 University Of Tartu Methylation and microrna markers of early-stage non-small cell lung cancer
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
WO2013120089A1 (en) 2012-02-10 2013-08-15 Raindance Technologies, Inc. Molecular diagnostic screening assay
EP2844768B1 (en) 2012-04-30 2019-03-13 Raindance Technologies, Inc. Digital analyte analysis
US10526655B2 (en) 2013-03-14 2020-01-07 Veracyte, Inc. Methods for evaluating COPD status
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
EP2986762B1 (en) 2013-04-19 2019-11-06 Bio-Rad Laboratories, Inc. Digital analyte analysis
WO2014173905A2 (en) * 2013-04-23 2014-10-30 Institut D'investigació Biomèdica De Bellvitge (Idibell) Methods and kits for prognosis of stage i nsclc by determining the methylation pattern of cpg dinucleotides
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
EP3080299B1 (en) * 2013-12-09 2020-09-30 Rush University Medical Center Biomarkers of rapid progression in advanced non-small cell lung cancer
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
EP3090063B1 (en) 2013-12-31 2019-11-06 Bio-Rad Laboratories, Inc. Method for detection of latent retrovirus
US20170335396A1 (en) 2014-11-05 2017-11-23 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
US10927417B2 (en) 2016-07-08 2021-02-23 Trustees Of Boston University Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6255293B1 (en) * 1998-07-24 2001-07-03 Yeda Research And Development Co., Ltd. Prevention of metastasis with 5-aza-2′-deoxycytidine

Also Published As

Publication number Publication date
WO2002044331A3 (en) 2003-09-04
WO2002044331A2 (en) 2002-06-06
US20050123969A1 (en) 2005-06-09
US20050142594A1 (en) 2005-06-30
US20030224509A1 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
AU2002236507A1 (en) Dap-kinase and hoxa9, two human genes associated with genesis, progression, and aggressiveness of non-small cell lung cancer
AU2001294943A1 (en) Nucleic acid sequences differentially expressed in cancer tissue
AU5481000A (en) Combination cancer therapy comprising adenosine and deaminase enzyme inhibitor
AU2001261007A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2001249549A1 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
AU2002311869A1 (en) Breast cancer-associated genes and uses thereof
AU5691699A (en) Human genes differentially expressed in colorectal cancer
AUPQ923100A0 (en) Treatment of prostate cancer
AU2002251366A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
AU1453301A (en) Methods of reversing drug resistance in cancer cells
AU2001240909A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
AU2001259062A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2001289283A1 (en) Patient stratification for cancer therapy based on genomic dna microarray analysis
AU2002352566A1 (en) Use of corrinoids in the treatment of skin diseases
WO2003060111A3 (en) Cancer-specific mutants of b-raf genes and uses thereof
AU2002215111A1 (en) Ruthenium-aryl-compounds in cancer therapy
AU2001273127A1 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2006107751A3 (en) Combined therapy utilizing reduction of dna methyltansferase expression and/or activity and interferon
AU2003231803A1 (en) Treatment of cancer with mefloquire
AU2002366195A1 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
AU1576501A (en) Methods to enhance and confine gene expression in cancer therapy
AU4328399A (en) Nucleic acid-cobalamin complexes and their use in gene therapy
AU2003292227A1 (en) Combined antisense oligonucleotide cancer therapy
AU4860299A (en) (zap-3) tumor associated genes and their uses
AU2002316688A1 (en) Lipophilin complexes for use in cancer diagnosis and therapy